Ardelyx, Inc. Enters Material Definitive Agreement

TL;DR

Ardelyx just signed a big deal, could be huge.

AI Summary

Ardelyx, Inc. announced on August 7, 2024, that it has entered into a material definitive agreement. The company, previously known as Nteryx Inc., is incorporated in Delaware and headquartered in Waltham, Massachusetts.

Why It Matters

This filing indicates a significant new contract or partnership for Ardelyx, Inc., which could impact its future business operations and financial performance.

Risk Assessment

Risk Level: medium — Entering into a material definitive agreement can carry significant risks related to the terms, obligations, and potential outcomes of the agreement.

Key Players & Entities

• ARDELYX, INC. (company) — Registrant
• NTERYX INC (company) — Former Company Name
• August 7, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 400 Fifth Avenue , Suite 210 , Waltham , Massachusetts 02451 (address) — Principal Executive Offices
• 001-36485 (identifier) — SEC File Number

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 ARDX The Nasdaq Global Market Indicat

Filing Documents

• ardx-20240807.htm (8-K) — 30KB
• exhibit101-xardelyxcatalen.htm (EX-10.1) — 287KB
• ardx-20240807_g1.jpg (GRAPHIC) — 3KB
• 0001628280-24-036749.txt ( ) — 502KB
• ardx-20240807.xsd (EX-101.SCH) — 2KB
• ardx-20240807_lab.xml (EX-101.LAB) — 22KB
• ardx-20240807_pre.xml (EX-101.PRE) — 13KB
• ardx-20240807_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On On August 7, 2024, Ardelyx, Inc. (the "Company") entered into a Commercial Supply Agreement (the "Supply Agreement") with Catalent Pharma Solutions, LLC ("Catalent"). The Supply Agreement is effective as of July 23, 2024. The Supply Agreement provides that Catalent will perform tableting, testing, release and bulk packaging of IBSRELA ("Product") in accordance with the specifications, target yields, and other terms and conditions set forth in the Supply Agreement. During the term of the Supply Agreement, the Company has agreed to purchase, and Catalent has agreed to manufacture, a minimum number of batches of Product per contract year, subject to the terms and conditions set forth in the Supply Agreement. The Company will pay Catalent the agreed upon unit prices for Product, which will be adjusted on an annual basis, beginning January 1, 2025, by an amount equal to the increase in the applicable producer price index. The Company will also pay certain other maintenance fees and expenses as contemplated by the Supply Agreement. The initial term of the Supply Agreement will continue until December 31, 2028, unless terminated earlier by one of the parties. Thereafter, the Supply Agreement will automatically renew for successive terms of two years until terminated by one of the parties. The Supply Agreement provides for termination by either party due to a material breach by the other party, and certain other extenuating circumstances, in each case after the applicable cure period (if any). The foregoing description of the terms of the Supply Agreement is not complete and is qualified in their entirety by reference to the Supply Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Commercial Supply Agreement, dated August 7, 2024 and effective as of July 23, 2024, by and between the Company and Catalent . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). Portions of the exhibit, marked by brackets, have been omitted because the omitted information (i) is not material and (ii) is the type that the Company treats as private or confidential.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 12, 2024 ARDELYX, INC. By: /s/ Justin Renz Justin Renz Chief Financial and Operations Officer

View Full Filing

View this 8-K filing on SEC EDGAR